A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Brief description of study
The purpose of the study is to determine how well tucatinib works with trastuzumab for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations). All participants will get both tucatinib and trastuzumab. The trial will also look at what side effects happen. The study drug tucatinib is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-01641
ClinicalTrials.gov Identifier: NCT04579380
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
